News | February 08, 2025
Aurbindo Pharma posts Q3 FY25 profit at Rs. 846 Cr
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
It will bring together renowned global experts in the field to discuss groundbreaking advances in biomaterials and their clinical applications
Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,
Arth by Emcure is a specialized range of supplements designed to address the unique health and wellness needs of women, enabling them to lead healthier and happier lives across all stages
AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
The camp, operational daily from 12 PM to 4 PM, offers free health check-ups, blood pressure monitoring
Subscribe To Our Newsletter & Stay Updated
